title: The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
abstract: Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Although ethnicity also contributes to MetS risk, the majority of the studies on the relationship of SGAs to this syndrome come from Western countries, whereas few reports have come from Asian countries, especially regarding patients taking a single SGA. We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months. We evaluated the prevalence of MetS in our sample as well as the indirect standardized prevalence ratio (ISPR) using data from the 4th Korean National Health and Nutrition Examination Survey (KNHNES, 2007). The prevalence of MetS in our sample (n=145) was 31.7%, and the ISPR was 2.09. Male patients had a higher prevalence of MetS than female patients (odds ratio [OR]=4.18, 95% CI=1.93-9.03). The ISPR of male patients was 2.67 and statistically significant, whereas the ISPR of female patients was not significant. In our sample, the frequency of abnormal MetS subcomponents occurred in descending order: increased waist circumference, increased triglyceride levels, decreased HDL-cholesterol levels, elevated blood pressure and elevated fasting blood glucose levels. Patients who received aripiprazole were significantly less likely to have MetS. However, a logistic regression showed that age and sex, but not the type of antipsychotic, its dose or the use of antidepressants, were significantly related to the presence of MetS. There were no statistically significant differences among SGAs in terms of MetS subcomponent abnormalities of after adjusting for age and sex. In conclusion, only male Korean patients with schizophrenia who received a monotherapy of aripiprazole, olanzapine or risperidone for more than three months were more likely to have MetS than the general population.
authors.affiliation: Department of Neuropsychiatry, Seoul National University Hospital, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Republic of Korea.
authors.forename: Nam Young
authors.initials: NY
authors.lastname: Lee
authors.forename: Se Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Dong Chung
authors.initials: DC
authors.lastname: Jung
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Kim
authors.forename: Han Young
authors.initials: HY
authors.lastname: Yu
authors.forename: Ki Hye
authors.initials: KH
authors.lastname: Sung
authors.forename: Ung Gu
authors.initials: UG
authors.lastname: Kang
authors.forename: Yong Min
authors.initials: YM
authors.lastname: Ahn
authors.forename: Yong Sik
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068180:Aripiprazole; D044466:Asian People; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008499:Medical Records; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology*; D008875:Middle Aged; D000077152:Olanzapine; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D015363:Quinolones / Q000009:adverse effects* / Q000627:therapeutic use; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D012737:Sex Factors; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D018967:Risperidone; D000077152:Olanzapine